Argatroban Anticoagulation for Heparin Induced Thrombocytopenia After Heartmate 3 Implantation: A Case Series

Heparin-induced thrombocytopenia (HIT) is a rare but potentially fatal immune-mediated complication of heparin therapy. Its incidence is higher after left ventricular assist device (LVAD) implantation compared with other cardiac procedures. While bivalirudin is the most frequently reported alternative anticoagulant in this setting, evidence on argatroban use remains limited. We describe three cases of HIT following HeartMate 3 LVAD implantation, all managed with argatroban.

Two patients were successfully transitioned to acenocoumarol (international normalized ratio 2-2.5) and discharged without hemocompatibility-related adverse events, without antiplatelet therapy. The third patient, with multiple thrombophilic disorders (homozygous G20210A prothrombin mutation, low protein C, positive lupus anticoagulant, and mild hyperhomocysteinemia), developed ventilator-associated pneumonia and septic shock, experienced mild bleeding at puncture and tracheostomy sites, and died postoperatively; anticoagulation transition was not achieved. In our cohort, HIT incidence was 10% overall (30 LVADs) and 15% among HeartMate 3 implants (20 LVADs), aligning with prior reports.

Argatroban appears to be an effective and safe alternative anticoagulant for HIT after LVAD implantation, enabling platelet recovery without a significant increase in bleeding or thrombotic events. Differentiating complications attributable to HIT or argatroban from those inherent to LVAD support remains challenging, given the device's intrinsic risks of thrombosis, bleeding, and mortality.